X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs STERLING BIOTECH - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD STERLING BIOTECH LUPIN LTD/
STERLING BIOTECH
 
P/E (TTM) x 28.9 -0.4 - View Chart
P/BV x 3.0 0.0 21,476.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN LTD   STERLING BIOTECH
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
STERLING BIOTECH
Dec-13
LUPIN LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,46511 13,952.4%   
Low Rs7273 21,385.3%   
Sales per share (Unadj.) Rs349.626.8 1,304.1%  
Earnings per share (Unadj.) Rs5.6-15.0 -37.2%  
Cash flow per share (Unadj.) Rs29.6-5.5 -541.4%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.354.9 547.2%  
Shares outstanding (eoy) m452.08267.87 168.8%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.10.3 1,209.3%   
Avg P/E ratio x197.2-0.5 -42,440.3%  
P/CF ratio (eoy) x37.1-1.3 -2,912.7%  
Price / Book Value ratio x3.60.1 2,881.9%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,5021,862 26,615.6%   
No. of employees `00017.01.4 1,258.6%   
Total wages/salary Rs m28,647547 5,239.0%   
Avg. sales/employee Rs Th9,273.65,303.3 174.9%   
Avg. wages/employee Rs Th1,681.0403.8 416.2%   
Avg. net profit/employee Rs Th147.4-2,959.0 -5.0%   
INCOME DATA
Net Sales Rs m158,0427,181 2,200.9%  
Other income Rs m1,50443 3,529.3%   
Total revenues Rs m159,5457,223 2,208.8%   
Gross profit Rs m31,475947 3,324.0%  
Depreciation Rs m10,8592,543 427.0%   
Interest Rs m2,0444,377 46.7%   
Profit before tax Rs m20,076-5,931 -338.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,885-1,924 -149.9%   
Profit after tax Rs m2,513-4,007 -62.7%  
Gross profit margin %19.913.2 151.0%  
Effective tax rate %14.432.4 44.3%   
Net profit margin %1.6-55.8 -2.8%  
BALANCE SHEET DATA
Current assets Rs m122,09514,335 851.7%   
Current liabilities Rs m50,95649,809 102.3%   
Net working cap to sales %45.0-494.0 -9.1%  
Current ratio x2.40.3 832.6%  
Inventory Days Days85403 21.0%  
Debtors Days Days120171 70.3%  
Net fixed assets Rs m129,87655,432 234.3%   
Share capital Rs m904268 337.5%   
"Free" reserves Rs m134,86613,935 967.8%   
Net worth Rs m135,77114,701 923.5%   
Long term debt Rs m64,2459,478 677.8%   
Total assets Rs m263,05473,988 355.5%  
Interest coverage x10.8-0.4 -3,049.5%   
Debt to equity ratio x0.50.6 73.4%  
Sales to assets ratio x0.60.1 619.0%   
Return on assets %1.70.5 345.8%  
Return on equity %1.9-27.3 -6.8%  
Return on capital %3.7-6.4 -57.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m53,1411,860 2,857.4%   
Fx outflow Rs m19,33525 77,680.6%   
Net fx Rs m33,8071,835 1,842.4%   
CASH FLOW
From Operations Rs m17,5121,719 1,018.9%  
From Investments Rs m-14,073-3,148 447.0%  
From Financial Activity Rs m-14,9211,426 -1,046.3%  
Net Cashflow Rs m-11,482-3 337,697.1%  

Share Holding

Indian Promoters % 46.6 33.9 137.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 0.0 -  
FIIs % 31.9 9.9 322.2%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.1 39.3 25.7%  
Shareholders   98,259 21,482 457.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ASTRAZENECA PHARMA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS